The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead Vt Regulatory News (BVT)

Share Price Information for Baronsmead Vt (BVT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.00
Bid: 51.50
Ask: 54.50
Change: 0.00 (0.00%)
Spread: 3.00 (5.825%)
Open: 53.00
High: 53.00
Low: 53.00
Prev. Close: 53.00
BVT Live PriceLast checked at -
Baronsmead Venture Trust is an Investment Trust

To achieve long-term investment returns for private investors by investing primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on AIM.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allotment of Shares and Total Voting Rights

15 Feb 2024 14:00

RNS Number : 3209D
Baronsmead Venture Trust PLC
15 February 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY MEMBER STATE OF THE EEA (OTHER THAN ANY MEMBER STATE OF THE EEA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETED), OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY INVESTMENTS IN ANY JURISDICTION.

Baronsmead Venture Trust plc

LEI: 213800VQ1PQHOJXDDQ88

15 February 2024

Allotment of Shares and Total Voting Rights

The Board of Baronsmead Venture Trust plc (the "Company") announced on 24 November 2023 that the Company, together with Baronsmead Second Venture Trust plc, had published a prospectus (the "Prospectus") in relation to offers for subscription to raise up to £30 million in aggregate with the discretion to utilise over-allotment facilities to raise up to a further £20 million in aggregate (the "Offers" and each an "Offer").

On 15 February 2024 and in accordance with the Allotment Formula set out in the Prospectus, the Company allotted 7,702,241 Ordinary Shares of 10 pence each (the "New Ordinary Shares") in the capital of the Company pursuant to the second allotment under the Offer conditional only on Admission (the timetable for which is set out in more detail below). The New Ordinary Shares were issued at prices of between 56.92 pence per New Ordinary Share and 59.68 pence per New Ordinary Share, depending on the amount of Offer Costs, any Initial Commission waived, any Initial Adviser Charges, any Early Bird Discount associated with an Application and based on the net asset value per Ordinary Share as at 31 January 2024 (being the last published net asset value per Ordinary Share as announced on 7 February 2024, adjusted for dividends following the ex-dividend date).

Application will shortly be made for the New Ordinary Shares to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the premium segment of London Stock Exchange plc's main market for listed securities ("Admission"). It is expected that Admission will occur and dealing will commence in the New Ordinary Shares on or around 22 February 2024. When issued, the New Ordinary Shares will rank pari passu with the existing Ordinary Shares.

As a result of the issue, the total number of Ordinary Shares in issue will be 372,225,504 (excluding the 33,187,409 Ordinary Shares currently held in Treasury) with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company will be 372,225,504. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

The New Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 10 business days of allotment. The New Ordinary Shares will be eligible for settlement through CREST with effect from Admission.

Unless the context requires otherwise, terms defined in the Prospectus have the same meaning where used in this announcement.

For further information please contact:

Baronsmead VCT Investor Relations

020 7382 0999

baronsmeadvcts@greshamhouse.com

Important Information

This Announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This Announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in Baronsmead Venture Trust plc or Baronsmead Second Venture Trust plc (together the "Companies") in any jurisdiction, including in or into Australia, Canada, Japan, the Republic of South Africa, the United States or any member state of the EEA (other than any member state of the EEA where the Companies' securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this Announcement except on the basis of information in the prospectus (the "Prospectus") in its final form, published on 24 November 2023 by Baronsmead Venture Trust plc and Baronsmead Second Venture Trust plc, together with the supplementary prospectus published on 19 January 2024 (the "Supplementary Prospectus"), in connection with the Offer. A copy of the Prospectus and Supplementary Prospectus is available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website (http://www.baronsmeadvcts.co.uk). Approval of the Prospectus and Supplementary Prospectus by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus and Supplementary Prospectus. Potential investors are recommended to read the Prospectus and Supplementary Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Companies' securities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEUVSORSNUUAAR
Date   Source Headline
3rd Sep 20203:30 pmRNSNet Asset Value(s)
6th Aug 20202:45 pmRNSNet Asset Value(s)
3rd Aug 20202:30 pmRNSTotal Voting Rights
30th Jul 20206:10 pmRNSTransaction in Own Shares
22nd Jul 20207:00 amRNSIntention to Fundraise
17th Jul 202011:00 amRNSNet Asset Value(s)
1st Jul 20207:00 amRNSTotal Voting Rights
10th Jun 20201:10 pmRNSTransaction in Own Shares
4th Jun 20205:00 pmRNSNet Asset Value(s)
4th Jun 20207:00 amRNSDividend Declaration
4th Jun 20207:00 amRNSHalf-year Report
12th May 20203:30 pmRNSNet Asset Value(s)
5th May 20205:00 pmRNSNet Asset Value(s)
8th Apr 20203:00 pmRNSNet Asset Value(s)
1st Apr 202012:58 pmRNSTotal Voting Rights
30th Mar 20205:28 pmRNSTransaction in Own Shares
25th Mar 20204:50 pmRNSNet Asset Value(s)
18th Mar 202010:39 amRNSOffer for Subscription - Update
10th Mar 20203:53 pmRNSDirector/PDMR Shareholding
6th Mar 20203:30 pmRNSNet Asset Value(s)
6th Mar 20202:57 pmRNSUpdate on the Offer for Subscription
2nd Mar 20204:05 pmRNSTotal Voting Rights
27th Feb 20203:11 pmRNSIssue of new shares
26th Feb 20203:44 pmRNSResult of AGM
7th Feb 202010:00 amRNSNet Asset Value(s)
3rd Feb 20207:00 amRNSTotal Voting Rights
27th Jan 20205:37 pmRNSDirector/PDMR Shareholding
24th Jan 20208:15 amRNSTransaction in Own Shares
23rd Jan 202011:45 amRNSIssue of New Shares
17th Jan 202012:01 pmRNSDirector Declaration
9th Jan 20203:00 pmRNSReplacement Net Asset Value(s)
9th Jan 202010:10 amRNSNet Asset Value(s)
2nd Jan 20209:00 amRNSTotal Voting Rights
30th Dec 20193:56 pmRNSTransaction in Own Shares
13th Dec 201912:41 pmRNSOffer Update - Change To Allotment Date
5th Dec 20195:00 pmRNSNet Asset Value(s)
2nd Dec 20194:42 pmRNSTotal Voting Rights
28th Nov 20194:35 pmRNSTransaction in Own Shares
25th Nov 20194:58 pmRNSDirector/PDMR Shareholding
25th Nov 20193:35 pmRNSPublication of Suppl.Prospcts
25th Nov 20197:00 amRNSAnnual Financial Report for the y/e 30/09/2019
20th Nov 201912:31 pmRNSIssue of New Shares
6th Nov 20195:40 pmRNSPDMR Shareholding
6th Nov 20195:15 pmRNSNet Asset Value(s)
1st Nov 201911:41 amRNSTotal Voting Rights
11th Oct 20194:00 pmRNSNet Asset Value(s)
10th Oct 20195:37 pmRNSTransaction in Own Shares
4th Oct 20199:00 amRNSPublication of a Prospectus
1st Oct 20195:53 pmRNSTotal Voting Rights
30th Sep 20195:31 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.